참고문헌 (31)

1. Van Duijn C. Alzheimer's disease, genetic and environmental？factors. Eur Psychiatry. 1998;13:217-8. 

   상세보기

2. Service NHI. National health insurance corporation - alzheimer's？(f00 and g30) treatment statistics for the number of patients and total？treatment costs. Korea: Public Data Portal; 2022. 

3. Tariot PN, Cummings JL, Katz IR, et al. A randomized,？double-blind, placebo-controlled study of the efficacy and safety of？donepezil in patients with alzheimer's disease in the nursing home？setting. J Am Geriatr Soc. 2001;49(12):1590-9. 

4. Alzforum Foundation. Therapeutics: Tacrine. 2023. Available from: https://www.alzforum.org/therapeutics/tacrine. Accessed on Oct. 30,？2023. 

5. FDA. Drugs@fda: Fda-approved drugs. 2021. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on Oct.？30, 2023. 

6. Kim J, Lee J, Jeong JH, Kang M, Bang JS. Study of the drugs？prescribed on alzheimer's disease: From the insurance claims data of？korea national health insurance service. Korean J Clin Pharm.？2014;24(4):255-64. 

7. Huang L-K, Chao S-P, Hu C-J. Clinical trials of new drugs for？alzheimer disease. J Biomed Sci. 2020;27(1):1-13. 

8. Korea Pharmaceutical Information Center. Kpic drug classification -？pharmaceutical information service 2021. Available from: https://www.health.kr/searchIngredient/KPICeffect.asp. Accessed on Oct.？30, 2023. 

9. Zhu X-C, Tan L, Wang H-F, et al. Rate of early onset alzheimer's？disease: A systematic review and meta-analysis. Ann Transl Med.？2015;3(3):38. 

   상세보기

10. Mejias-Trueba M, Perez-Moreno MA, Fernandez-Arche MA.？Systematic review of the efficacy of statins for the treatment of？alzheimer's disease. Clin Med. 2018;18(1):54. 

    상세보기

11. Yu J-T, Xu W, Tan C-C, et al. Evidence-based prevention of？alzheimer's disease: Systematic review and meta-analysis of 243？observational prospective studies and 153 randomised controlled？trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201-9. 

    상세보기

12. Park H, Lee S, An S. Clinical effects of zinc supplementation in？patients hospitalized with covid-19: A systematic review and meta-analysis. Korean J Clin Pharm. 2021;31(2):136-44. 

    원문보기 상세보기

13. Cochrane. Chapter 8: Assessing risk of bias in a randomized trial？2022. Available from https://training.cochrane.org/handbook/archive/v6.3/chapter-08. Accessed December 21, 2023. 

14. Cho, JH. Theory and Practice of Meta-Analysis. J Rhinol.？2020;27(2):83-9 

    상세보기

15. Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety,？and biomarker outcomes of atabecestat in preclinical alzheimer？disease: A truncated randomized phase 2b/3 clinical trial. JAMA？Neurol. 2021;78(3):293-301. 

    상세보기

16. Cohen S, He P, Benea ML, et al. Item-level analysis of clinical？measures in patients with early symptomatic alzheimer's disease？following treatment with high-dose aducanumab in the phase 3？study emerge. Alzheimers Dement. 2021;17(S9):e057619. 

17. Budd Haeberlein S, Aisen P, Barkhof F, et al. Two randomized？phase 3 studies of aducanumab in early alzheimer's disease. J Prev？Alzheimers Dis. 2022;9(2):197-210. 

    

18. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early？alzheimer's disease. N Engl J Med. 2021;384(18):1691-704. 

    상세보기

19. Ostrowitzki S, Bittner T, Sink KM, et al. Evaluating the safety and？efficacy of crenezumab vs placebo in adults with early alzheimer？disease: Two phase 3 randomized placebo-controlled trials. JAMA？Neurol. 2022;79(11):1113-21. 

    상세보기

20. Swanson C, Dhadda S, Hodgkinson M, et al. Lecanemab, an anti-Aβ Protofibril antibody: Updated data from a randomized, double-blind phase 2b proof of concept clinical trial and open-label？extension in early alzheimer's disease. J Neurol Sci. 2021;429:100. 

21. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early？alzheimer's disease. N Engl J Med. 2023;388(1):9-21. 

    상세보기

22. Teng E, Manser PT, Pickthorn K, et al. Safety and efficacy of？semorinemab in individuals with prodromal to mild alzheimer？disease: A randomized clinical trial. JAMA Neurol. 2022;79(8):758-67. 

    상세보기

23. Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized,？double-blind, placebo-controlled, parallel-group, phase 3 clinical？trial of sodium oligomannate for mild-to-moderate alzheimer's？dementia. Alzheimers Res Ther. 2021;13(1):62. 

24. Prins ND, Harrison JE, Chu HM, Blackburn K, Alam JJ, Scheltens？P. A phase 2 double-blind placebo-controlled 24-week treatment？clinical study of the p38 alpha kinase inhibitor neflamapimod in？mild alzheimer's disease. Alzheimers Res Ther. 2021;13(1):106. 

25. Hirst WD, Stean TO, Rogers DC, et al. Sb-399885 is a potent,？selective 5-ht6 receptor antagonist with cognitive enhancing？properties in aged rat water maze and novel object recognition？models. Eur J Pharmacol. 2006;553(1-3):109-19. 

    상세보기

26. Nirogi R, Jayarajan P, Abraham R, et al. Effects of masupirdine？(suvn-502) on agitation/aggression and psychosis in patients with？probable alzheimer's disease: A post hoc analysis. Alzheimers？Dement. 2022;18:e062695. 

27. Haddad HW, Malone GW, Comardelle NJ, Degueure AE, Kaye？AM, Kaye AD. Aducanumab, a novel anti-amyloid monoclonal？antibody, for the treatment of alzheimer's disease: A comprehensive？review. Health Psychol Res. 2022;10(1):31925. 

28. Breijyeh Z, Karaman R. Comprehensive review on alzheimer's？disease: Causes and treatment. Molecules. 2020;25(24):5789. 

    상세보기

29. Hannestad J, Duclos T, Chao W, et al. Safety and tolerability of？grf6019 infusions in severe alzheimer's disease: A phase ii double-blind placebo-controlled trial. J Alzheimers Dis. 2021;81(4):1649-62. 

    상세보기

30. Koh SH, Kwon HS, Choi SH, et al. Efficacy and safety of gv1001 in？patients with moderate-to-severe alzheimer's disease already？receiving donepezil: A phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021;13(1):66. 

31. Wang T, Kuang W, Chen W, et al. A phase ii randomized trial of？sodium oligomannate in alzheimer's dementia. Alzheimers Res？Ther. 2020;12(1):110.